Orchestra BioMed Holdings, Inc.: investing cash flow
Investing cash flow for Orchestra BioMed Holdings, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Orchestra BioMed Holdings, Inc. financial histories
What this measure means
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
Exact concept: us-gaap:NetCashProvidedByUsedInInvestingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2022-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -26,941,000 | USD | 2026-03-12 | 10-K · 0001104659-26-026754 |
| 2024-01-01 | 2024-12-31 | 13,089,000 | USD | 2026-03-12 | 10-K · 0001104659-26-026754 |
| 2023-01-01 | 2023-12-31 | 10,687,000 | USD | 2025-03-31 | 10-K · 0001558370-25-004161 |
| 2022-01-01 | 2022-12-31 | -64,122,000 | USD | 2024-03-27 | 10-K · 0001558370-24-004083 |
Related financial histories
- Orchestra BioMed Holdings, Inc.: total assets
- Orchestra BioMed Holdings, Inc.: total liabilities
- Orchestra BioMed Holdings, Inc.: stockholders equity
- Orchestra BioMed Holdings, Inc.: cash and cash equivalents
- Orchestra BioMed Holdings, Inc.: net income or loss
- Orchestra BioMed Holdings, Inc.: operating cash flow
- Orchestra BioMed Holdings, Inc.: capital expenditure payments
- Orchestra BioMed Holdings, Inc.: revenue
- Orchestra BioMed Holdings, Inc.: financing cash flow
- Orchestra BioMed Holdings, Inc.: retained earnings or deficit
- Orchestra BioMed Holdings, Inc.: basic weighted-average shares
- Orchestra BioMed Holdings, Inc.: diluted weighted-average shares
- Orchestra BioMed Holdings, Inc.: basic earnings per share
- Orchestra BioMed Holdings, Inc.: diluted earnings per share
- Orchestra BioMed Holdings, Inc.: net property, plant and equipment
- Orchestra BioMed Holdings, Inc.: share-based compensation expense
- Orchestra BioMed Holdings, Inc.: operating income or loss
- Orchestra BioMed Holdings, Inc.: current assets
- Orchestra BioMed Holdings, Inc.: current liabilities
- Orchestra BioMed Holdings, Inc.: current accounts payable
- Orchestra BioMed Holdings, Inc.: net current accounts receivable
- Orchestra BioMed Holdings, Inc.: net inventory
- Orchestra BioMed Holdings, Inc.: cost of revenue
- Orchestra BioMed Holdings, Inc.: selling, general and administrative expense
- Orchestra BioMed Holdings, Inc.: research and development expense
Inspect the source
- Entity
- Orchestra BioMed Holdings, Inc. / CIK 0001814114
- Captured
- 2026-09-21T17:33:55.958Z
- SEC response SHA-256
f490c393d405fb139d3488fa9c027ee1423073551fb45f7969fec942006123e2
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001814114.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))